Emotional expression during attention-deficit/hyperactivity disorders treatment: Initial assessment of treatment effects
Emotional expression during attention-deficit/hyperactivity disorders treatment: Initial assessment of treatment effects
复制标题
DOI：
10.1089/cap.2006.0018
复制
发表时间：
2007-02-01
影响因子：
1.9
通讯作者：
Swindle, R.
中科院分区：
文献类型：
--
作者：
Kratochvil, C. J.;Faries, D.;Swindle, R.
目的：本研究的目的是利用新开发的评估注意力缺陷多动障碍（ADHD）儿童情绪表达的量表，初步探讨托莫西汀和兴奋剂对情绪表达的影响。方法：收集两项研究中父母评定的儿童表情与情绪量表（EESC）。在横断面验证研究中，完成了EESC以评估儿童目前的治疗情况和回顾性既往用药情况。在一项随机、安慰剂对照的托莫西汀试验中，在基线和终点收集EESC。结果：验证研究中，托莫西汀组（n = 74）与兴奋剂组（n = 105） EESC评分差异无统计学意义。从兴奋剂切换到阿托西汀的患者（n = 40）比切换到另一种兴奋剂的患者（n = 21）在情绪表达方面有更大的改善（p = 0.008）。在临床试验中，观察到情绪表达恶化率无差异（托莫西汀8.8%，安慰剂12.3%;p = 0.440）。结论：在现有药物治疗基础上，情绪表达治疗无差异。然而，需要转换药物的兴奋剂患者可能会通过转换到阿托西汀在情绪表达方面有更大的改善。
Objective: The purpose of this research was to provide an initial examination of the effects of atomoxetine and stimulants on emotional expression using a newly developed scale for assessing emotional expression in children with attention-deficit/hyperactivity disorder (ADHD).Method: The parent-rated Expression and Emotion Scale for Children (EESC) was collected during two studies. During a cross-sectional validation study, the EESC was completed to assess the child's current treatment and retrospectively for previous medication. In a randomized, placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint.Results: In the validation study, no statistically significant differences in EESC scores were found between groups taking atomoxetine (n = 74) and stimulants (n = 105). Patients who switched from a stimulant to atomoxetine (n = 40) had greater improvement in emotional expression than those switched to another stimulant (n = 21) (p = 0.008). In the clinical trial, no difference in rates of worsening of emotional expression were observed (atomoxetine 8.8%, placebo 12.3%; p = 0.440).Conclusion: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have greater improvements in emotional expression by switching to atomoxetine.